Home LiteratureArticle Details
PMID: 29541203 Published · ppublish English Journal Article

Transcriptome-derived stromal and immune scores infer clinical outcomes of patients with cancer.

Oncology letters ·Vol. 15 ·No. 4 ·2018-04-00 ·Pages 4351-4357

Liu W, Ye H, Liu YF, Xu CQ, Zhong YX, Tian T, Ma SW, Tao H, Li L, Xue LC, He HQ

Abstract

The stromal and immune cells that form the tumor microenvironment serve a key role in the aggressiveness of tumors. Current tumor-centric interpretations of cancer transcriptome data ignore the roles of stromal and immune cells. The aim of the present study was to investigate the clinical utility of stromal and immune cells in tissue-based transcriptome data. The 'Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data' (ESTIMATE) algorithm was used to probe diverse cancer datasets and the fraction of stromal and immune cells in tumor tissues was scored. The association between the ESTIMATE scores and patient survival data was asessed; it was indicated that the two scores have implications for patient survival, metastasis and recurrence. Analysis of a colorectal cancer progression dataset revealed that decreased levels immune cells could serve an important role in cancer progression. The results of the present study indicated that trasncriptome-derived stromal and immune scores may be a useful indicator of cancer prognosis.

Keywords
immune cells recurrence stromal cells survival
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Liu Wei
School of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou, Fujian 350002, P.R. China. | Department of Pathology, Human Centrifuge Medical Training Center, Institute of Aviation Medicine of Chinese PLA Air Force, Beijing 100089, P.R. China.
Ye Hua
Department of Gastroenterology, Ningbo Medical Treatment Center Lihuili Hospital, Ningbo, Zhejiang 315040, P.R. China.
Liu Ying-Fu
Department of Cell Biology, Logistics University of Chinese Armed Police Forces, Tianjin 300309, P.R. China.
Xu Chao-Qun
School of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou, Fujian 350002, P.R. China.
Zhong Yue-Xian
School of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou, Fujian 350002, P.R. China.
Tian Tian
School of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou, Fujian 350002, P.R. China.
Ma Shi-Wei
School of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou, Fujian 350002, P.R. China.
Tao Huan
School of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou, Fujian 350002, P.R. China.
Li Ling
School of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou, Fujian 350002, P.R. China.
Xue Li-Chun
School of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou, Fujian 350002, P.R. China.
He Hua-Qin
School of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou, Fujian 350002, P.R. China.
References (32)
32 references, click to expand
  1. Stromal gene expression predicts clinical outcome in breast cancer.
    Nat Med. 2008 May;14(5):518-27 PMID: 18438415
  2. Interactions between the tumor suppressor p53 and immune responses.
    Curr Opin Oncol. 2013 Jan;25(1):85-92 PMID: 23150340
  3. An assessment of computational methods for estimating purity and clonality using genomic data derived from heterogeneous tumor tissue samples.
    Brief Bioinform. 2015 Mar;16(2):232-41 PMID: 24562872
  4. Proteomics. Tissue-based map of the human proteome.
    Science. 2015 Jan 23;347(6220):1260419 PMID: 25613900
  5. Drug resistance: the stroma's contribution.
    Nat Chem Biol. 2012 Sep;8(9):739 PMID: 22907084
  6. Gene expression in fixed tissues and outcome in hepatocellular carcinoma.
    N Engl J Med. 2008 Nov 6;359(19):1995-2004 PMID: 18923165
  7. Inferring tumour purity and stromal and immune cell admixture from expression data.
    Nat Commun. 2013;4:2612 PMID: 24113773
  8. Tumour evolution inferred by single-cell sequencing.
    Nature. 2011 Apr 7;472(7341):90-4 PMID: 21399628
  9. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
    J Clin Oncol. 2005 Oct 20;23(30):7518-28 PMID: 16172461
  10. The fabric of cancer cell biology-Weaving together the strands.
    Cancer Cell. 2002 Feb;1(1):3-10 PMID: 12086880
  11. Origin and interpretation of cancer transcriptome profiling: the essential role of the stroma in determining prognosis and drug resistance.
    EMBO Mol Med. 2015 Aug 03;7(11):1385-7 PMID: 26240076
  12. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer.
    Genome Biol. 2007;8(8):R157 PMID: 17683518
  13. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.
    Science. 2011 Mar 25;331(6024):1565-70 PMID: 21436444
  14. Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells.
    Mol Oncol. 2015 Dec;9(10):2054-62 PMID: 26607741
  15. Gene co-expression analysis identifies common modules related to prognosis and drug resistance in cancer cell lines.
    Int J Cancer. 2014 Dec 15;135(12):2795-803 PMID: 24771271
  16. Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer.
    Gut. 2013 Aug;62(8):1100-11 PMID: 22735568
  17. The Relationship of Immune Cell Signatures to Patient Survival Varies within and between Tumor Types.
    PLoS One. 2015 Sep 23;10(9):e0138726 PMID: 26398410
  18. Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?
    Clin Transl Immunology. 2017 Mar 17;6(3):e134 PMID: 28435677
  19. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
    Clin Cancer Res. 2004 Mar 15;10 (6):2158-67 PMID: 15041737
  20. A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype.
    Breast Cancer Res. 2014 Jul 25;16(4):407 PMID: 25060555
  21. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression.
    Nat Med. 2011 Mar;17(3):320-9 PMID: 21383745
  22. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.
    Cell Death Differ. 2014 Jan;21(1):15-25 PMID: 23787994
  23. From cancer genomics to precision oncology--tissue's still an issue.
    Cell. 2014 Jun 19;157(7):1509-14 PMID: 24949964
  24. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer.
    Nat Genet. 2015 Apr;47(4):320-9 PMID: 25706628
  25. Integrative analysis of the cancer transcriptome.
    Nat Genet. 2005 Jun;37 Suppl:S31-7 PMID: 15920528
  26. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.
    Ann Surg Oncol. 2010 Jun;17(6):1471-4 PMID: 20180029
  27. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.
    Am J Clin Pathol. 2011 Jan;135(1):54-61 PMID: 21173124
  28. High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway.
    Clin Cancer Res. 2012 Mar 1;18(5):1374-85 PMID: 22241791
  29. Concerted down-regulation of immune-system related genes predicts metastasis in colorectal carcinoma.
    BMC Cancer. 2014 Feb 05;14:64 PMID: 24495478
  30. Stromal contribution to the colorectal cancer transcriptome.
    Nat Genet. 2015 Apr;47(4):312-9 PMID: 25706627
  31. Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation.
    Cancer Cell. 2012 Nov 13;22(5):571-84 PMID: 23153532
  32. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.
    J Clin Oncol. 2010 Oct 1;28(28):4316-23 PMID: 20805453
Article Info
Journal
Oncology letters
Abbr.
Oncol Lett
ISSN
1792-1074
DOI
10.3892/ol.2018.7855
Published
2018-04-00
Epub
2018-00-25
Pages
4351-4357
Language
English
Region
Greece
NLM ID
101531236
PMCID
PMC5835954
External Links
PubMed source DOI: 10.3892/ol.2018.7855 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2